Positive selection immunomagnetic separation kit

Human chronic B-cell leukemia, MEC-1 cells were obtained from the DSMZ). All experiments with cell lines were conducted within 6 months after thawing or obtaining from DSMZ. Cell line authentication was done by DSMZ. The DSMZ uses short tandem repeat profiling for characterization and authentication of cell lines. Cells were cultured in Iscove's Modified Dulbecco's Medium with 10% heat-inactivated FBS and 1% penicillin/streptomycin. Cells were passaged two to three times per week and frozen in aliquots in liquid nitrogen. HK cells were kindly provided and characterized by Jianguo Tao (Moffitt Cancer Center, Tampa, FL), cultured in RPMI with 10% FBS, and maintained as previously described (32 (link)). Exponentially growing cells were used for all described experiments. Primary CLL cells (Supplementary Table S1) were obtained with informed consent (in accordance with the Declaration of Helsinki) under a research protocol approved by the Institutional Review Board of Kansas University Medical Center (Kansas City, KS; Protocol #12392) or the NIH (7 (link), 30 (link)). Primary CLL cells were isolated from the peripheral blood and CD19⁺ B cells were purified, utilizing a positive selection immunomagnetic separation kit (Stem Cell Technologies). Normal human CD34⁺ cells were obtained from delinked, deidentified human cord blood samples.